Vaccinations in patients with hematological malignancies

详细信息    查看全文

• 作者：C. Tsigrelis^a ; ^b ; P. Ljungman^c ; ^d ; ^{per.ljungman@ki.se" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Vaccination ; Stem cell transplantation ; Hematological malignancy ; Influenza ; Pneumococci ; Varicella-zoster virus
• 刊名：Blood Reviews
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：30
• 期：2
• 页码：139-147
• 全文大小：392 K

文摘

Patients with hematological malignancies are at risk for a number of infections that are potentially preventable by vaccinations such as pneumococcal infections and influenza. Treatment, especially with anti-B-cell antibodies and hematopoietic stem cell transplantation (HSCT), negatively impacts the response to vaccination for several months. It is therefore recommended that patients be vaccinated before initiating immunosuppressive therapy if possible. The risk of side-effects with inactivated vaccines is low, but care has to be taken with live vaccines, such as varicella-zoster virus vaccine, since severe and fatal complications have been reported. HSCT patients require repeated doses of most vaccines to achieve long-lasting immune responses. New therapeutic options for patients with hematological malignancies that are rapidly being introduced into clinical practice will require additional research regarding the efficacy of vaccinations. New vaccines are also in development that will require well-designed studies to ascertain efficacy and safety.